This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Protection for Clinical Research

John W. Yarbro, MD, PhD; Lee E. Mortenson, MS

JAMA. 1985;253(5):684-685.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

TODAY we face a crisis in clinical research that demands that attention be directed to a problem that physicians have not had to worry about in the past: the impact of reimbursement for patient care on the progress of medical science. Until this year, the costs for patients involved in clinical trials were paid in two ways: the research costs of data collection and analysis, experimental drugs, and such were paid by research grants; the patient-care costs were paid by the patient or the insurance carrier.

The advent of the prospective payment system and diagnosis-related group (DRG) reimbursement dramatically alters this system and changes the incentives. Under the DRG system, the hospital receives a fee fixed by diagnosis, and administrators are likely to show little enthusiasm for anything that increases the cost of care. Extra laboratory tests or x-ray films beyond a bare minimum will not be encouraged. The pattern . . . [Full Text PDF of this Article]

Author Affiliations
From the Association of Community Cancer Centers, Rockville, Md.

Footnotes
Reprint requests to the Association of Community Cancer Centers, 11600 Nebel St, Rockville, MD 20852 (Mr Mortenson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?